Dottikon ES Holding AG/€DESN
1D1W1MYTD1Y5YMAX
Capital at risk
About Dottikon ES Holding AG
Dottikon ES Holding AG is a Switzerland-based company specializing in the production of high-quality performance chemicals for the pharmaceutical and chemical industries. It primarily focuses on hazardous chemical reactions, leveraging its expertise in safety and reliability to deliver a range of active pharmaceutical ingredients (APIs) and intermediates. Founded in 1913, the company has a long-standing presence in the chemical industry. Headquartered in Dottikon, Switzerland, the company strategically emphasizes its capabilities in complex chemical processes to serve a global clientele. Dottikon's operations are supported by its state-of-the-art facilities which enable it to handle chemically intensive processes efficiently and safely.
- Ticker
- €DESN
- Sector
- Health
- Primary listing
- XGAT
- Employees
- 900
- Headquarters
- Dottikon, Switzerland
- Website
- dottikon.com
DESN Metrics
BasicAdvanced
€3.8B
35.06
€7.92
0.94
-
Price and volume
Market cap
€3.8B
Beta
0.94
52-week high
€360.24
52-week low
€323.33
Average daily volume
3K
Financial strength
Current ratio
3.555
Quick ratio
2.097
Long term debt to equity
0.119
Total debt to equity
0.119
Interest coverage (TTM)
87.17%
Profitability
EBITDA (TTM)
159.682
Gross margin (TTM)
61.25%
Net profit margin (TTM)
23.55%
Operating margin (TTM)
27.36%
Effective tax rate (TTM)
12.22%
Revenue per employee (TTM)
€517,980
Management effectiveness
Return on assets (TTM)
5.45%
Return on equity (TTM)
9.92%
Valuation
Price to earnings (TTM)
35.06
Price to revenue (TTM)
8.256
Price to book
3.32
Price to tangible book (TTM)
3.33
Price to free cash flow (TTM)
123.991
Free cash flow yield (TTM)
0.81%
Free cash flow per share (TTM)
2.24
Growth
Revenue change (TTM)
12.03%
Earnings per share change (TTM)
-1.91%
3-year revenue growth (CAGR)
10.52%
10-year revenue growth (CAGR)
13.57%
3-year earnings per share growth (CAGR)
5.67%
10-year earnings per share growth (CAGR)
20.68%
Bulls say / Bears say
FY2025/26 sales increased 11.2% to CHF428.4 million and EBITDA rose 5.4% to CHF148.0 million. This shows that demand is still growing despite the transition to a much larger production base. (Dottikon ES Holding AG)
The new 100 m³ multipurpose plant and API drying plant have passed regulatory inspections and entered cGMP production. All four first-phase drying lines are operational, and the remaining production lines are due to come on stream during FY2026/27, creating a potential near-term utilisation lift. (Dottikon ES Holding AG, DCAT Value Chain Insights)
Dottikon has invested about CHF1 billion over the past and coming five years in small-molecule cGMP, high-potency API and related infrastructure, with most spending already completed. If outsourcing demand continues, this specialist capacity could strengthen its competitive position and support longer-term growth. (DCAT Value Chain Insights, Dottikon ES Holding AG)
FY2025/26 sales rose 11.2%, but EBITDA margin fell to 34.6% from 36.5% and net income dropped 1.9%. Higher staffing, materials and depreciation show that the new capacity is putting pressure on profits before it contributes fully to sales. (Dottikon ES Holding AG)
Dottikon says weak biotech financing, drug-price regulation, tariffs and geopolitical risks could delay drug launches and reduce development projects. That could slow the customer pipeline feeding its new plants. (MarketScreener Canada)
The shares trade on roughly 39 times earnings, above the European pharmaceuticals industry average cited by Simply Wall St, while FY2026 EPS missed analyst expectations by 17%. A premium multiple leaves less room for further execution or margin disappointments. (Simply Wall St)
Data summarised monthly by Lightyear AI. Last updated on 17 Sept 2026.
Upcoming events
No upcoming events
Funds containing DESN
AllEURGBP
Fund name | Fund size | €DESN weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.06% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.06% |
Vanguard ESG Global All Cap£V3AB | £905M | 0.00% |
Vanguard ESG Global All Cap€V3AA | €1.1B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.